Prolia (Denosumab) Cost in Kentucky 2026

What Does Prolia (Denosumab) Cost Without Insurance in Kentucky?

The manufacturer list price set by Amgen for a single 60 mg prefilled syringe of Prolia is $1,500. Average cash-pay pricing across Kentucky retail pharmacies in 2026 mirrors this figure closely, with most pharmacies charging the full wholesale acquisition cost to uninsured patients.

Because Prolia is administered as a subcutaneous injection every six months, the annual drug cost alone runs approximately $3,000. Add in the office visit or infusion center fee for administration (typically $50 to $150 per visit depending on the provider), and total annual out-of-pocket spending for an uninsured Kentucky patient ranges from $3,100 to $3,300.

This pricing places Prolia among the more expensive osteoporosis treatments available. For comparison, generic alendronate (oral bisphosphonate) costs $4 to $30 per month at most Kentucky pharmacies. The price gap is significant, but the drugs work through different mechanisms. Denosumab is a RANK ligand inhibitor that reduces osteoclast formation and activity, while bisphosphonates bind to bone mineral and inhibit osteoclast resorption from within 1. The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared to placebo 1.

Patients paying out-of-pocket should request a pharmacy benefits check before filling. Some independent pharmacies in Lexington, Louisville, and Bowling Green may offer slightly lower cash pricing through preferred wholesaler agreements.

Kentucky Medicaid Coverage for Prolia

Kentucky Medicaid does not cover Prolia (denosumab) as of 2026. This applies to both fee-for-service Medicaid and the managed care organizations (MCOs) that administer Kentucky's Medicaid program, including Aetna Better Health of Kentucky, Humana Healthy Horizon, Molina Healthcare, and WellCare of Kentucky.

The exclusion creates a gap for low-income patients with osteoporosis. Kentucky's Medicaid population skews older in its disability categories, and osteoporosis prevalence among women aged 50 and older in Appalachian Kentucky exceeds national averages according to CDC bone health surveillance data 2.

For Medicaid patients who cannot tolerate oral bisphosphonates (the first-line covered alternative), options include:

Zoledronic acid (Reclast), an intravenous bisphosphonate given once yearly, which most Kentucky MCOs do cover with prior authorization. The HORIZON-Key Fracture Trial showed zoledronic acid reduced vertebral fracture risk by 70% over 3 years 3.

Requesting a medical exception or formulary override through the MCO. Approval rates are low (estimated 15 to 25% based on national commercial plan data), but documented bisphosphonate intolerance or contraindication strengthens the case.

Applying for the Amgen Safety Net Foundation program, which provides Prolia at no cost to qualifying patients with household income at or below 300% of the federal poverty level 4.

Insurance Coverage and Prior Authorization in Kentucky

Most commercial insurance plans available in Kentucky do cover Prolia, though with conditions. Prior authorization is standard across nearly all carriers. The typical approval criteria include:

A confirmed diagnosis of osteoporosis (T-score of -2.5 or lower at the hip or spine on DXA scan, or history of fragility fracture). Documented trial and failure of, intolerance to, or contraindication for at least one oral bisphosphonate (usually alendronate or risedronate). Clinical documentation from the prescribing physician.

Among the largest commercial insurers operating in Kentucky, Anthem Blue Cross Blue Shield, Humana, CareSource, and UnitedHealthcare all list Prolia on their specialty pharmacy formularies at a Tier 4 or Tier 5 level. Copays at these tiers typically range from $75 to $250 per fill before any manufacturer copay assistance is applied.

The Endocrine Society's 2020 clinical practice guideline recommends denosumab as an appropriate first-line option for postmenopausal women at high fracture risk, particularly those with renal impairment where bisphosphonates carry additional risks 5. Citing this guideline in prior authorization requests can support medical necessity arguments.

Medicare Part B covers Prolia under its "incident to" billing rules when administered in a physician's office. Kentucky Medicare beneficiaries typically pay 20% coinsurance after meeting their Part B deductible, making the out-of-pocket cost approximately $300 per injection. Medigap plans may cover this coinsurance partially or fully.

How the Amgen Savings Card Works in Kentucky

Amgen offers the Prolia Complete copay assistance program for commercially insured patients. The program is accepted at pharmacies and physician offices throughout Kentucky. Here is how it works:

Eligible patients receive up to $1 to 500 in copay assistance per injection. This effectively covers the entire cost for most commercially insured patients, reducing out-of-pocket expense to $0 in many cases. The card covers up to $3,000 per calendar year (two injections).

Eligibility requirements: the patient must have commercial insurance that covers Prolia, must not be enrolled in any federal or state healthcare program (Medicare, Medicaid, TRICARE, VA), and must be a U.S. resident.

Enrollment takes approximately 5 minutes online or by phone. The card can be used at any participating pharmacy or physician office in Kentucky. Most rheumatology and endocrinology practices in the state are familiar with the enrollment process.

One limitation that patients should understand: the savings card benefit counts toward the patient's out-of-pocket maximum on some insurance plans but not others. Under accumulator adjustment programs (increasingly common among larger employers), manufacturer copay assistance may not count toward the deductible or out-of-pocket maximum. Kentucky has not passed accumulator adjustment legislation as of 2026, unlike some neighboring states.

Dr. Andrea Singer, Director of Bone Density at MedStar Georgetown University Hospital and former president of the National Osteoporosis Foundation, has noted: "Patient assistance programs are critical for medication adherence in osteoporosis, where the consequences of stopping therapy are not immediately apparent to patients but clinically significant" 6.

Compounded Denosumab Through 503A Pharmacies in Kentucky

Compounded denosumab is available in Kentucky through licensed 503A compounding pharmacies. This is legal under both federal law (the Drug Quality and Security Act of 2013) and Kentucky Board of Pharmacy regulations.

A 503A pharmacy compounds medications pursuant to individual patient prescriptions. This differs from 503B outsourcing facilities, which can produce compounded drugs in larger batches without patient-specific prescriptions. Both pathways are operational in Kentucky for biologic compounds.

Key considerations for compounded denosumab in Kentucky:

Cost is typically lower than the branded Prolia product. Some 503A pharmacies advertise compounded denosumab at substantially reduced prices, though exact pricing varies by pharmacy and is not standardized.

The compounded product is not FDA-approved and does not carry the same regulatory oversight as the branded product manufactured by Amgen. The FDA's position on compounded biologics remains that they should be prepared in accordance with current good manufacturing practices, but 503A pharmacies operate under state pharmacy board oversight rather than direct FDA inspection 7.

Patients considering compounded denosumab should verify that their chosen pharmacy holds active Kentucky Board of Pharmacy licensure, maintains appropriate cold-chain storage for biologic compounds, and can provide certificates of analysis for their compounded preparations.

Insurance plans do not cover compounded denosumab. Patients using this option pay entirely out-of-pocket, which may still represent savings over the branded product without insurance coverage.

Telehealth Prescribing of Prolia in Kentucky

Kentucky permits telehealth prescribing of Prolia (denosumab). A physician can evaluate a patient via telehealth, review DXA scan results and laboratory work, and write the prescription without an in-person visit.

Kentucky's telehealth parity law (KRS 211.336) requires commercial insurers to cover telehealth services at the same rate as in-person services. This means the consultation to establish the prescription can be billed to insurance. The law was made permanent after temporary COVID-era expansions.

The practical workflow for Kentucky patients:

The prescribing visit can occur via telehealth. The actual injection must still be administered in person, either at a physician's office, infusion center, or by a home health nurse. Some Kentucky home health agencies will administer the injection at the patient's residence after pharmacy delivery, which is particularly relevant for rural patients in Eastern Kentucky where specialist access is limited.

HealthRX telehealth consultations are available to Kentucky residents for osteoporosis evaluation and Prolia prescribing, with same-week appointment availability in most cases.

Comparing Prolia Costs to Alternatives in Kentucky

The cost picture for osteoporosis treatment in Kentucky varies dramatically by drug class.

Generic alendronate (Fosamax): $4 to $30 per month at Kentucky pharmacies, covered by Medicaid. Annual cost: $48 to $360.

Generic risedronate (Actonel): $15 to $60 per month. Annual cost: $180 to $720.

Zoledronic acid (generic Reclast): $300 to $800 per infusion annually, often covered by Medicaid with prior authorization.

Prolia (denosumab): $3,000 per year at list price.

Tymlos (abaloparatide): approximately $3,200 per month ($38,400 per year). Kentucky Medicaid does not cover this.

Evenity (romosozumab): approximately $2,800 per month for the 12-month course ($33,600 total). Reserved for very high fracture risk patients. The ARCH trial demonstrated romosozumab followed by alendronate reduced fracture risk by 48% compared to alendronate alone over 24 months 8.

For patients specifically weighing Prolia against zoledronic acid (the two most common injectable options), a network meta-analysis published in the Journal of Bone and Mineral Research found comparable fracture reduction efficacy between the two agents, though denosumab showed a modest advantage in hip BMD gains at 24 months 9. The American Association of Clinical Endocrinologists (AACE) 2020 guidelines position both as appropriate options for high-risk patients, noting that "denosumab may be preferred in patients with renal impairment given the lack of renal clearance" 10.

Discontinuation Risks and Cost Planning

One financial planning consideration specific to denosumab: stopping therapy triggers rapid bone loss. The FREEDOM extension study showed that patients who discontinued denosumab after long-term use experienced vertebral fracture rates that rebounded to pre-treatment levels within 12 to 18 months 11. Multiple vertebral fractures have been reported in the post-discontinuation period.

This means that starting Prolia creates an ongoing financial commitment. Patients and prescribers should verify insurance stability and financial ability to maintain therapy before initiating. If discontinuation becomes necessary (due to cost, insurance change, or clinical decision), current guidelines recommend transitioning to a bisphosphonate (typically zoledronic acid or oral alendronate) to preserve bone density gains.

For Kentucky patients on commercial insurance who are approaching Medicare eligibility, this transition period requires planning. Medicare Part B covers Prolia, so continuity is possible, but the coverage structure changes (20% coinsurance vs. commercial copay), and the Amgen savings card is not usable with Medicare.

Kentucky patients aged 63 to 64 who are starting Prolia should confirm with their prescriber that a transition plan is in place for the Medicare coverage switch at age 65, ensuring no gap in therapy that could trigger rebound bone loss.